The direct bilirubin-to-albumin ratio (DBAR) has emerged as a reliable prognostic marker for assessing 28-day mortality in critically ill patients with cirrhosis, as demonstrated by a study utilizing the MIMIC-IV database. Cirrhosis patients in ICUs face high mortality rates, and traditional models like MELD and Child-Pugh have limitations due to complexity and subjective parameters.
The direct bilirubin-to-albumin ratio (DBAR) has emerged as a reliable prognostic marker for assessing 28-day mortality in critically ill patients with cirrhosis, as demonstrated by a study utilizing the MIMIC-IV database. Cirrhosis patients in ICUs face high mortality rates, and traditional models like MELD and Child-Pugh have limitations due to complexity and subjective parameters. DBAR, which combines two key liver function markers—direct bilirubin (reflecting hepatocyte injury) and albumin (indicating liver synthetic ability)—offers a simpler, objective, and accessible alternative.
The study analyzed data from 509 adult cirrhotic patients and found that elevated DBAR values were strongly associated with worse outcomes. Patients with DBAR ≥ 4 were classified as high-risk and demonstrated significantly lower survival rates (56.9% vs. 18.4% mortality within 28 days). Multivariate Cox regression analysis confirmed DBAR as an independent predictor of mortality (HR 1.16), alongside age, lactate, INR, and vasoactive medication use. Kaplan-Meier survival curves and nonlinear restricted cubic spline analysis further validated DBAR’s prognostic accuracy.
DBAR showed good predictive performance (AUC 0.702), comparable to the MELD score (AUC 0.744) and superior to albumin alone (AUC 0.549). Machine learning ranked DBAR among the top predictors of cirrhosis prognosis, alongside lactate and BUN. External validation using the eICU-CRD database confirmed its reproducibility (AUC ≈ 0.71). DBAR’s predictive effect was consistent across subgroups, though variations were noted in patients with ascites and hepatorenal syndrome.
Clinically, elevated DBAR signals severe hepatic dysfunction, inflammation, and malnutrition, making it a practical and cost-effective biomarker for bedside mortality risk assessment in ICU settings.
Introduction: Acute kidney injury (AKI) is a frequent and life-threatening complication of cirrhosis, with management often complicated by inaccurate assessment of intravascular volume and the presence of cirrhotic cardiomyopathy (CCM). This prospective study evaluated whether...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Adults with Fontan-type circulation are increasingly recognized to develop Fontan-associated liver disease and portal hypertension. This prospective study explored the prevalence, anatomical distribution, and hemodynamic characteristics of esophageal varices (EV), with particular emphasis on...
Introduction: Acute-on-chronic liver failure (ACLF) is characterized by overwhelming systemic inflammation and immune dysregulation, leading to high short-term mortality. This study used advanced single-cell and spatial transcriptomic technologies to define the immune landscape of ACLF...
Introduction: Despite advances in the management of portal hypertension, mortality after variceal bleeding remains high in patients with cirrhosis. Experimental and clinical studies suggest that statins may improve portal hypertension and hepatic vascular function. This...
Introduction: Acute liver failure (ALF) complicated by cerebral oedema carries a high risk of early mortality, primarily due to hyperammonemia and intracranial hypertension. The optimal timing of continuous renal replacement therapy (CRRT) in these critically...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.